Moteur de recherche d’entreprises européennes
Financement de l’UE (3 953 988 €) : Contrôle métabolique de la croissance cellulaire par mTOR en santé et maladie : une formation pluridisciplinaire Hor17/07/2024 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Contrôle métabolique de la croissance cellulaire par mTOR en santé et maladie : une formation pluridisciplinaire
MENTOR is a multi-disciplinary training network which focuses on the mTOR pathway, a central mechanistic hub that integrates nutritional cues and controls cell growth and metabolism. Aberrant activation of mTOR underlies monogenic diseases with broad spectrum of pathological manifestations, including tissue overgrowth, polycystic kidneys and neuropsychiatric disorders affecting around two million of people worldwide. To avoid the medical errancy of patients in different clinical departments and surgical mutilations, approaches of personalized medicine depending on the genetic landscape need to be implemented, taking advantage of suitable pharmacological products. The overall goal of the MENTOR research program is to: delineate molecular mechanisms of fundamental and aberrant mTOR functions, preclinically decipher the pathophysiology of mTOR, develop a novel arsenal of drugs to selectively target the pathway and provide proof-of-concept support for such interventions. This ambition can only be achieved by the multidisciplinary research program that MENTOR has conceived, through the training of a new generation of scientists at Graduate Schools of biology, pharmacy, chemistry or medicine that will become the leaders of mTOR research in both public and private sectors. MENTOR will establish a collaborative and efficient network from academia to industry, involving patient associations and clinicians with impact on scientific community and society.
| Assistance Publique Hopitaux de Paris | ? |
| EBERHARD KARLS UNIVERSITAET TUEBINGEN | 521 078 € |
| Fondazione Telethon ETS | 259 438 € |
| Fundacion Sector Publico Estatal Centro Nacional Investigaciones Oncologicas Carlos III | 251 971 € |
| Idryma Technologias Kai Erevnas | 240 098 € |
| Institut du Cerveau et de la Moelle Epiniere | 282 694 € |
| Katholieke Universiteit Leuven | 262 620 € |
| Miedzynarodowy Instytut Mechanizmow i Maszyn Molekularnych Polskiej Akademii Nauk | 226 512 € |
| MIMETAS B.V. | 274 370 € |
| PD-VALUE B.V. | 274 370 € |
| UNIVERSITAETSKLINIKUM ESSEN | 521 078 € |
| UNIVERSITAIR MEDISCH CENTRUM UTRECHT | 274 370 € |
| Universite Paris Cite | 565 387 € |
https://cordis.europa.eu/project/id/101168624
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Assistance Publique Hopitaux de Paris, Paris.
